Singapore Paincare Holdings Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Singapore Paincare Holdings han disminuido a una tasa media anual de -10.2%, mientras que en la industria Healthcare los beneficios crecieron en un 15.1% anualmente. Los ingresos han ido creciendo a una tasa media de 30.1% al año.

Información clave

-10.2%

Tasa de crecimiento de los beneficios

-86.0%

Tasa de crecimiento del BPA

Crecimiento de la industria Healthcare	9.7%
Tasa de crecimiento de los ingresos	30.1%
Rentabilidad financiera	0.8%
Margen neto	-1.4%
Última actualización de beneficios	31 Dec 2023

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Singapore Paincare Holdings. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

Catalist:FRQ Ingresos, gastos y beneficios (SGD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
31 Dec 23	25	0	0
30 Sep 23	24	0	0
30 Jun 23	22	-1	0
31 Mar 23	22	1	1
31 Dec 22	22	2	1
30 Sep 22	21	3	1
30 Jun 22	19	4	1
31 Mar 22	17	4	1
31 Dec 21	15	4	0
30 Sep 21	13	3	0
30 Jun 21	11	2	0
31 Mar 21	11	2	0
31 Dec 20	10	1	0
30 Sep 20	10	2	0
30 Jun 20	10	2	0
31 Mar 20	9	2	0
31 Dec 19	7	2	0
30 Sep 19	6	2	0
30 Jun 19	4	1	1
30 Jun 18	4	1	0
30 Jun 17	4	1	0

Ingresos de calidad: FRQ actualmente no es rentable.

Margen de beneficios creciente: FRQ actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: FRQ no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 10.2% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de FRQ en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: FRQ no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Healthcare (-2%).

Rentabilidad financiera

Alta ROE: FRQ tiene una rentabilidad financiera negativa (0.8%), ya que actualmente no es rentable.

Singapore Paincare Holdings Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Full year 2023 earnings released: S$0.003 loss per share (vs S$0.022 profit in FY 2022)

Full year 2023 earnings released: S$0.003 loss per share (vs S$0.022 profit in FY 2022)

Singapore Paincare Holdings Limited to Report Fiscal Year 2023 Results on Aug 29, 2023

First half 2023 earnings released

Full year 2022 earnings released: EPS: S$0.022 (vs S$0.013 in FY 2021)

Full year 2022 earnings released: EPS: S$0.022 (vs S$0.013 in FY 2021)

Recent updates

High number of new directors

Singapore Paincare Holdings Limited Announces the Appointment of Soh Chiong Siong as Financial Controller, Effective April 22, 2024

Insufficient new directors

Now 22% undervalued after recent price drop

Singapore Paincare Holdings Limited Announces Yap Beng Tat, Richard Resigns as Independent Non-Executive Director

Singapore Paincare Holdings Limited Announces Resignation of Lim Mong Ai, Karen as Financial Controller

Now 20% undervalued

Singapore Paincare Holdings Limited Proposes Final Dividend (Tax Exempt One-Tier) for the Financial Year Ended 30 June 2023, Payable on November 17, 2023

Full year 2023 earnings released: S$0.003 loss per share (vs S$0.022 profit in FY 2022)

Singapore Paincare Holdings Limited Proposes Final Dividend (Tax Exempt One-Tier) for the Financial Year Ended 30 June 2023

Singapore Paincare Holdings Limited, Annual General Meeting, Oct 27, 2023

Full year 2023 earnings released: S$0.003 loss per share (vs S$0.022 profit in FY 2022)

Singapore Paincare Holdings Limited to Report Fiscal Year 2023 Results on Aug 29, 2023

New minor risk - Financial data availability

Singapore Paincare Holdings Limited Appoints Lim Mong Ai, Karen as Financial Controller, Effective July 1, 2023

First half 2023 earnings released

Singapore Paincare Holdings Limited Appoints Lim Kah Meng as Chairman of the Remuneration Committee and A Member of the Audit Committee and the Nominating Committee

Upcoming dividend of S$0.012 per share

Singapore Paincare Holdings Limited Approves Final Dividend (Tax-Exempt One-Tier) for the Financial Year Ended 30 June 2022

Full year 2022 earnings released: EPS: S$0.022 (vs S$0.013 in FY 2021)

Singapore Paincare Holdings Limited Announces Cessation of Chong Weng Hoe as Independent Non-Executive Director, Chairman of Remuneration Committee and Member of the Audit Committee and Nominating Committee

Full year 2022 earnings released: EPS: S$0.022 (vs S$0.013 in FY 2021)

Singapore Paincare Holdings Limited Recommends Final Dividend

Singapore Paincare Holdings Limited Announces Promotion of Leow Yong Kin from Financial Controller to Chief Financial Officer

High number of new and inexperienced directors

High number of new and inexperienced directors

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings released: EPS S$0.013 (vs S$0.031 in FY 2020)

Full year 2021 earnings released: EPS S$0.013 (vs S$0.031 in FY 2020)

Singapore Paincare Holdings Limited Appoints Dr. Lim Kah Meng as Independent Non-Executive Director

First half 2021 earnings released: EPS S$0.004 (vs S$0.01 in 1H 2020)

Singapore Paincare Holdings Limited (Catalist:FRQ) completed the acquisition of 40% stake in KCS Anaesthesia Services Pte. Ltd from Kong Chee Sang.

New 90-day high: S$0.23

Singapore Paincare Holdings Limited (Catalist:FRQ) agreed to acquire 40% stake in Kong Chee Seng fro SGD 2.4 million.

Singapore Paincare Holdings Limited has completed a Follow-on Equity Offering in the amount of SGD 3.96 million.

Full year earnings released - EPS S$0.031

Singapore Paincare Holdings Limited (Catalist:FRQ) entered into agreement to acquire AE Medical Sengkang Private Limited from Wong Shing Yip for SGD 0.17 million.

Singapore Paincare Holdings Limited has completed an IPO in the amount of SGD 5.33412 million.

Desglose de ingresos y gastosBeta

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Desglose de ingresos y gastos
Beta